Glaucoma Clinical Trial
Official title:
Utility of Heidelberg Retina Tomograph in Monitoring Glaucoma Progression
Glaucoma is a chronic disease defined by characteristic changes in the optic nerve
associated initially with loss of peripheral vision and is treated by lowering intraocular
(inside the eye) pressure. It has been reported that noticeable changes to the optic nerve
caused by glaucoma may occur several years before changes in vision are noticed. Since
changes to the optic nerve and other eye structures due to glaucoma are irreversible, it is
important to develop tools for the earliest possible detection of changes due to glaucoma.
The Heidelberg Retina Tomograph (HRT) is a device that is used to produce a
three-dimensional map of the optic nerve and retina, and can be used to detect changes in
the optic nerve and retina over time. In previous studies, it has been shown to be useful
for the detection of changes due to glaucoma. However, the HRT when compared to other
techniques to evaluate the optic nerve such as stereophotography, was found to only somewhat
agree.
The current study will compare HRT to stereophotography to determine how good each one is at
looking and documenting changes in the optic nerve over time due to glaucoma. Using HRT to
initiate early topical medication or to change management requires knowing how well HRT
results predict the development of visual loss. Accordingly, the results of this study may
affect the management of glaucoma patients by optimizing the follow-up of people with this
condition and by initiating appropriate and more individualized treatments. Early treatment
is crucial for preventing further visual loss in patients with glaucoma or ocular
hypertension (high pressure inside the eye).
In glaucoma, treatment decisions depend on the development of morphologic and functional
damage. Therefore, damage serves as an indicator of management. Commonly, progression is
determined by various perimetric techniques.
However, it has been reported that clinically detectable glaucomatous structural alteration
of the ONH may precede the development of reproducible white on white and blue on yellow
visual field defects by up to several years.
The HRT is a confocal scanning laser tomography device that creates a three-dimensional
topographic analysis of the ONH and the peripapillary retina and includes a statistical
analysis to evaluate structural change over time.
This technique showed good sensitivity and high specificity in detecting glaucoma
progression when tested using computer simulation. The same good results were obtained by
the same authors, in another study, in a small subgroup of 16 patients who were monitored
for glaucomatous progression by both HRT and ONH stereophotographs for approximately 5.5
years.
However, in our recent retrospective study, our results demonstrated only fair agreement
between HRT and clinical judgment of ONH stereophotographs for progression in glaucoma, for
a mean follow-up time with HRT of 2.62 years. Although, the evaluation of the ONH
stereophotographs is necessarily subjective, it is widely accepted and has been shown to be
effective for evaluating change. Using the stereophotographs assessments as the "reference
standard", the HRT sensitivity was 78% and the specificity to 70%. The positive predictive
value of the HRT was 47.8%, while the negative predictive value was 90.3%.
According to the results of this study if the frequency of true positives and false
positives does not change with longer follow-up, treatment decisions would be based on a
test that may be in error 52.2% of the time.
Accordingly, our previous - and other studies - study demonstrated only fair agreement
between HRT and clinical judgment of ONH stereophotographs for progression in glaucoma. At
present, the available evidence does not appear to be sufficient to show that the addition
of HRT improves the ability to predict the development of clinical optic disc change and/or
visual field loss.
Therefore the aim of the current study is to investigate the clinical significance of the
HRT in monitoring glaucoma progression. In other words we will investigate how well HRT
results for glaucomatous progression are able to predict the future development of optic
disc and/or visual field changes in patients with OHT and glaucoma.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A |